Raffaella Lombardi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12308/publications.pdf

Version: 2024-02-01

45 papers	2,922 citations	236925 25 h-index	254184 43 g-index
45 all docs	45 docs citations	45 times ranked	3730 citing authors

#	Article	IF	Citations
1	Activation of PDGFRA signaling contributes to filamin Câ€“related arrhythmogenic cardiomyopathy. Science Advances, 2022, 8, eabk0052.	10.3	12
2	Haploinsufficiency ofTmem43in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy. Cardiovascular Research, 2021, 117, 2377-2394.	3.8	25
3	Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging. Journal of Cardiovascular Translational Research, 2020, 13, 238-244.	2.4	12
4	Arrhythmogenic Cardiomyopathy and Skeletal Muscle Dystrophies: Shared Histopathological Features and Pathogenic Mechanisms. Frontiers in Physiology, 2020, 11, 834.	2.8	5
5	Established and Emerging Mechanisms in the Pathogenesis of Arrhythmogenic Cardiomyopathy: A Multifaceted Disease. International Journal of Molecular Sciences, 2020, 21, 6320.	4.1	19
6	Identification of Genes and Pathways Regulated by Lamin A in Heart. Journal of the American Heart Association, 2020, 9, e015690.	3.7	9
7	Editorial of Special Issue â€œGenetics and Molecular Pathogenesis of Non-Ischemic Cardiomyopathiesâ€• International Journal of Molecular Sciences, 2020, 21, 9398.	4.1	2
8	DNA Damage Response/TP53 Pathway Is Activated and Contributes to the Pathogenesis of Dilated Cardiomyopathy Associated With LMNA (Lamin A/C) Mutations. Circulation Research, 2019, 124, 856-873.	4.5	95
9	Knock Down of Plakophillin 2 Dysregulates Adhesion Pathway through Upregulation of miR200b and Alters the Mechanical Properties in Cardiac Cells. Cells, 2019, 8, 1639.	4.1	18
10	Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies. Circulation Research, 2018, 122, 678-692.	4.5	54
11	Distinct Cellular Basis for Early Cardiac Arrhythmias, the Cardinal Manifestation of Arrhythmogenic Cardiomyopathy, and the Skin Phenotype of Cardiocutaneous Syndromes. Circulation Research, 2017, 121, 1346-1359.	4.5	26
12	Cardiac Fibro-Adipocyte Progenitors Express Desmosome Proteins and Preferentially Differentiate to Adipocytes Upon Deletion of the Desmoplakin Gene. Circulation Research, 2016, 119, 41-54.	4.5	85
13	Knockdown of Plakophilin 2 Downregulates miR-184 Through CpG Hypermethylation and Suppression of the E2F1 Pathway and Leads to Enhanced Adipogenesis In Vitro. Circulation Research, 2016, 119, 731-750.	4.5	43
14	The Hippo Pathway Is Activated and Is a Causal Mechanism for Adipogenesis in Arrhythmogenic Cardiomyopathy. Circulation Research, 2014, 114, 454-468.	4.5	227
15	Speckle-tracking analysis based on 2D echocardiography does not reliably measure left ventricular torsion. Clinical Physiology and Functional Imaging, 2013, 33, 117-121.	1.2	10
16	Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. Cardiovascular Research, 2013, 97, 44-54.	3.8	39
17	Genetics and sudden death. Current Opinion in Cardiology, 2013, 28, 272-281.	1.8	13
18	Human Molecular Genetic and Functional Studies Identify TRIM63 , Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy. Circulation Research, 2012, 111, 907-919.	4.5	117

#	Article	IF	Citations
19	Percutaneous treatment of patients with heart diseases: selection, guidance and follow-up. A review. Cardiovascular Ultrasound, 2012, 10, 16.	1.6	2
20	Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. European Journal of Clinical Investigation, 2011, 41, 527-538.	3.4	79
21	Molecular Genetics and Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy: A Disease of Cardiac Stem Cells. Pediatric Cardiology, 2011, 32, 360-365.	1.3	43
22	Nuclear Plakoglobin Is Essential for Differentiation of Cardiac Progenitor Cells to Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Research, 2011, 109, 1342-1353.	4.5	145
23	Arrhythmogenic right ventricular cardiomyopathy is a disease of cardiac stem cells. Current Opinion in Cardiology, 2010, 25, 222-228.	1.8	30
24	Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. European Journal of Clinical Investigation, 2010, 40, 976-983.	3.4	36
25	Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms. Circulation, 2009, 119, 1398-1407.	1.6	106
26	Genetic Fate Mapping Identifies Second Heart Field Progenitor Cells As a Source of Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Research, 2009, 104, 1076-1084.	4.5	135
27	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Medical Genetics, 2009, 10, 111.	2.1	43
28	Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovascular Research, 2008, 79, 109-117.	3.8	54
29	Enhanced Transmural Fiber Rotation and Connexin 43 Heterogeneity Are Associated With an Increased Upper Limit of Vulnerability in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circulation Research, 2007, 101, 1049-1057.	4.5	50
30	Myozenin 2 Is a Novel Gene for Human Hypertrophic Cardiomyopathy. Circulation Research, 2007, 100, 766-768.	4.5	168
31	Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Human Molecular Genetics, 2007, 16, 2463-2471.	2.9	74
32	Myocardial Texture in Hypertrophic Cardiomyopathy. Journal of the American Society of Echocardiography, 2007, 20, 1253-1259.	2.8	12
33	Abnormal blood-pressure response to exercise and oxygen consumption in patients with hypertrophic cardiomyopathy. Journal of Nuclear Cardiology, 2007, 14, 869-875.	2.1	15
34	Antifibrotic Effects of Antioxidant N-Acetylcysteine in a Mouse Model of Human Hypertrophic Cardiomyopathy Mutation. Journal of the American College of Cardiology, 2006, 47, 827-834.	2.8	105
35	Effect of hypertrophy on left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Heart International, 2006, 2, 106.	1.4	4
36	Effect of Hypertrophy on Left Ventricular Diastolic Function in Patients with Hypertrophic Cardiomyopathy. Heart International, 2006, 2, 182618680600200.	1.4	0

#	Article	IF	Citations
37	Suppression of canonical Wnt/Â-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. Journal of Clinical Investigation, 2006, 116, 2012-2021.	8.2	519
38	Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. American Journal of Cardiology, 2004, 94, 895-900.	1.6	114
39	Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: Comparison with normal subjects. Journal of Nuclear Cardiology, 2003, 10, 154-160.	2.1	9
40	Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy. Circulation, 2003, 108, 1455-1460.	1.6	185
41	Dobutamine Stress Echocardiography in Hypertrophic Cardiomyopathy. Cardiology, 2003, 100, 93-100.	1.4	11
42	Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2002, 40, 278-284.	2.8	80
43	Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope. American Journal of Cardiology, 2002, 89, 1405-1410.	1.6	17
44	Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. American Journal of Cardiology, 1999, 84, 309-315.	1.6	75
45	Clinical Significance of Diastolic Dysfunction and the Effect of Therapeutic Interventions. , 0, , 147-157.		0